Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

531P - Efficacy of vitamin C and zinc injections in the management of mucositis: A comparative observational study

Date

07 Dec 2024

Session

Poster Display session

Presenters

Chaitanya Patil

Citation

Annals of Oncology (2024) 35 (suppl_4): S1595-S1615. 10.1016/annonc/annonc1695

Authors

C.R. Patil1, N. Dhamne2, Y.S. Anap3, P.K. Tanawade3

Author affiliations

  • 1 Pain And Palliative Care, Kolhapur Cancer Centre, 416005 - Kolhapur/IN
  • 2 Medical Oncology Department, Kolhapur Cancer Centre, 416234 - Kolhapur/IN
  • 3 Radiation Oncology, Kolhapur Cancer Centre, 416234 - Kolhapur/IN

Resources

This content is available to ESMO members and event participants.

Abstract 531P

Background

Mucositis is a prevalent and debilitating complication of cancer treatments, notably chemotherapy and radiotherapy, leading to inflammation and ulceration of the mucous membranes. This condition significantly impairs the quality of life of patients by causing severe pain, difficulty in eating and swallowing, and increasing the risk of infections. Current management strategies for mucositis are often inadequate, prompting the need for more effective treatments. Recent studies suggest that vitamin C and zinc, known for their roles in immune function, antioxidant defense, and tissue repair, could be potential therapeutic agents for mucositis.

Methods

A comparative observational study was conducted at the Department of Pain and Palliative Medicine, Kolhapur Cancer Centre, Maharashtra, India, over six months from September 2023 to February 2024. The study included two cohorts: a historical cohort treated before September 2023 and a prospective cohort treated during the study period, each consisting of 30 patients. The prospective cohort received vitamin C (1g intravenously) and zinc (20mg intravenously) injections twice a day for 5 days in addition to standard care. Data on VAS pain scores, time to achieve a pain score of less than 3, Quality of Life (QOL) using the H&N 35 QOL scale, and hospital admissions were collected and analyzed.

Results

The prospective cohort demonstrated significantly better outcomes compared to the historical cohort. The mean VAS score post-treatment decreased to 6.0 in the prospective cohort versus 7.0 in the historical cohort (p=0.0402). The time to achieve a pain score of less than 3 was significantly shorter in the prospective cohort (9.0 days) compared to the historical cohort (12.0 days) (p=0.0485). Additionally, the total QOL score improved significantly in the prospective cohort, with a mean score of 35.0 compared to 60.0 in the historical cohort (p=0.0487). Hospital admissions were fewer in the prospective cohort (7%) compared to the historical cohort (17%) (p=0.2163).

Conclusions

Vitamin C and zinc injections significantly improved pain management, reduced the time to achieve pain relief, and enhanced the quality of life in patients with mucositis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.